Takeda And Shire - One Japan CEO's Take
The planned combination of Takeda and Shire has dominated headlines in recent weeks, but how is it viewed within the industry in Japan? One CEO shares his thoughts.
You may also be interested in...
Recent deal-making has seen new developments to further existing agreements, including Allergan licensing a depression candidate from the spinout of a company it bought in 2015. Also, updates on deals involving Celgene, AstraZeneca and Daiichi Sankyo.
Chugai's new CEO Tatsuro Kosaka took up his position in March and is charged with taking the major Japanese company through the next stage of development as key products reach the global market and others begin to face biosimilar competition. In this first part of a two-part exclusive interview, he outlines the firm's vision, approach to R&D and how the strategic alliance with Roche is playing out.
In this week's podcast edition of Five Must-Know Things: alarms sound over Omicron; Sanofi boosts vaccine pipeline via acquisition; J&J’s immunology plans; Chinese firms step onto world stage; and top execs share insights to shape India’s R&D push.